top of page

Longboard Pharma's CEO describes today's open label extension data for bexicaserin in Developmental and Epileptic Encephalopathies

  • blonca9
  • Jun 10, 2024
  • 1 min read

Kevin Lind explains how patients randomized to therapy and placebo crossover patients are seeing comparable reductions in seizure levels. He also discusses the regulatory path ahead as this programs looks to enter pivotal study(ies).



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

evaluate-logo-png_seeklogo-457165-2_edited.png

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

bottom of page